Hydralazine and Kidney Function

Introduction to Hydralazine's Renal Effects

• Hydralazine typically increases renal blood flow and maintains glomerular filtration rate in hypertensive patients with normal kidneys, according to the British Journal of Pharmacology 1
• The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend considering hydralazine-isosorbide dinitrate as a therapeutic option in patients intolerant of ACE inhibitors or ARBs due to renal insufficiency, with potential benefit unknown 2, 3

Direct and Indirect Renal Effects

• Hydralazine acts as a potent vasodilator through increased nitric oxide availability, which lowers blood pressure and potentially increases renal arterial flow, particularly demonstrated during intravenous administration in acute settings, as reported by the British Journal of Pharmacology 1
• The combination of hydralazine with isosorbide dinitrate has been shown to decrease mortality in patients with pre-existing renal failure, suggesting it can be safely used in this population when appropriately monitored, according to the British Journal of Pharmacology 1

Clinical Considerations and Monitoring

• The risk of hydralazine-induced lupus (which can involve the kidneys leading to renal dysfunction) increases with prolonged use, making this a critical consideration for long-term therapy, as noted by the British Journal of Pharmacology 1
• Hydralazine is renally excreted and accumulates in patients with chronic kidney disease, particularly when GFR falls below 30 mL/min, as stated by the British Journal of Pharmacology 1
• For African Americans with HFrEF who remain symptomatic despite optimal therapy with ACE inhibitors, beta blockers, and mineralocorticoid receptor antagonists, the addition of hydralazine-isosorbide dinitrate is recommended to reduce morbidity and mortality, according to the American College of Cardiology 2, 3, 4

Safe Use and Potential Pitfalls

• Do not confuse hydralazine's renal accumulation (requiring dose adjustment) with direct nephrotoxicity—the drug itself does not damage kidneys through toxic mechanisms in the vast majority of patients, as clarified by the British Journal of Pharmacology 1
• Avoid using hydralazine without monitoring in patients with GFR <30 mL/min, as significant drug accumulation occurs and dose reduction is necessary, and do not assume that worsening renal function in a patient on hydralazine is due to the drug without first evaluating for volume depletion, hypotension, or concomitant nephrotoxic medications, as warned by the British Journal of Pharmacology 1

Hydralazine and Isosorbide Dinitrate in Severe Renal Impairment

Introduction to Alternative Therapy

• The American College of Cardiology recommends hydralazine and isosorbide dinitrate as an alternative therapy in patients with severe renal impairment (GFR <30 mL/min/1.73 m²) and heart failure with reduced ejection fraction when ACE inhibitors, ARBs, or ARNi cannot be tolerated, with limited evidence based on older trials 5, 6
• The American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines suggest considering hydralazine-isosorbide dinitrate in patients intolerant of ACE inhibitors or ARBs due to renal insufficiency, although the potential benefit is unknown 5, 6

Primary Recommendation and Dosing

• The American College of Cardiology supports using hydralazine and isosorbide dinitrate to reduce morbidity or mortality in patients with current or prior symptomatic HFrEF who cannot be given an ACE inhibitor or ARB, based on a Class IIa recommendation from 2013 ACC/AHA guidelines 7, 8
• Initial dose: Hydralazine 25 mg three times daily plus isosorbide dinitrate 20 mg three times daily, with target dose of Hydralazine 75 mg three times daily plus isosorbide dinitrate 40 mg three times daily, but expecting lower doses in severe renal impairment 7, 8
• Titration schedule: Increase doses every 2-3 weeks as tolerated, monitoring blood pressure, symptoms, and renal function closely 9

Monitoring Requirements and Caveats

• Renal function and electrolyte monitoring: Check creatinine and potassium at 2-3 days following initiation, then monthly for 3 months, and every 3 months thereafter 9
• The evidence supporting hydralazine-isosorbide dinitrate in ACE inhibitor/ARB-intolerant patients is substantially weaker than for other indications, with recent observational datasets not confirming benefit in this population 5, 6
• If patients are unable to tolerate first-line agents due to renal insufficiency, referral to a heart failure specialist should be strongly considered for guidance on further management 5, 6

Strongest Evidence for Alternative Populations

• The strongest evidence for hydralazine-isosorbide dinitrate exists in African American patients with NYHA class III-IV HFrEF who remain symptomatic despite optimal therapy with ACE inhibitors (or ARBs), beta blockers, and mineralocorticoid receptor antagonists, with a Class I recommendation 5, 6, 7, 8

Hydralazine Use in Patients with Renal Impairment

Clinical Benefits and Safety Considerations

• The combination of hydralazine with isosorbide dinitrate has demonstrated mortality reduction in heart failure patients with pre-existing renal failure, according to the British Journal of Pharmacology 10
• The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend hydralazine-isosorbide dinitrate as a therapeutic option in patients intolerant of ACE inhibitors or ARBs due to renal insufficiency, though they acknowledge the evidence is weaker than for other indications 11
• Hydralazine can cause drug-induced lupus, which may involve the kidneys and lead to renal dysfunction, as reported in the British Journal of Pharmacology 10

Dosing Considerations in Renal Impairment

• In patients with severe renal impairment (GFR <30 mL/min), the dose of hydralazine should be reduced by 50% due to significant drug accumulation, and dosing intervals may need to be extended based on clinical response, as suggested by the British Journal of Pharmacology 10

Hydralazine Titration in Patients with Hypertension or Heart Failure and Impaired Renal Function

Initial Dosing and Titration Strategy

• The American Heart Association recommends starting with hydralazine 25 mg three times daily in patients with impaired renal function, and always initiating a beta-blocker and diuretic before starting hydralazine to prevent reflex tachycardia and sodium/water retention 12
• Baseline renal function, electrolytes, blood pressure, and heart rate should be checked before starting hydralazine, and hydralazine should be combined with isosorbide dinitrate in heart failure patients 13
• The American College of Cardiology recommends increasing doses every 2-3 weeks as tolerated, monitoring blood pressure, symptoms, and renal function closely, with a target dose of 75 mg three times daily (225 mg total daily) for patients with GFR ≥30 mL/min 13

Special Considerations for Heart Failure

• The American Heart Association recommends adding hydralazine 37.5 mg + isosorbide dinitrate 20 mg three times daily to optimal therapy for African American patients with heart failure with reduced ejection fraction (HFrEF) and NYHA class III-IV symptoms, with a target of hydralazine 75 mg + isosorbide dinitrate 40 mg three times daily, as a Class I recommendation with mortality benefit demonstrated in the A-HeFT trial 13, 14

Monitoring Requirements

• The American Heart Association recommends checking renal function and electrolytes at 2-3 days, 1 week, and monthly for the first 3 months after initiation, and every 3 months thereafter, with regular monitoring of blood pressure and watching for orthostatic hypotension, particularly in elderly patients 13

Parameters for Holding or Reducing Doses

• The American College of Cardiology recommends holding hydralazine if systolic BP <100 mmHg or diastolic BP <60 mmHg, heart rate >110 bpm, signs of drug-induced lupus develop, or serum creatinine increases significantly or GFR drops below 15 mL/min, and reducing dose by 50% if GFR falls below 30 mL/min during treatment or patient develops symptomatic hypotension or dizziness, with a maximum dose of 150 mg total daily to minimize risk of drug-induced lupus 12